GSK 2849466

Drug Profile

GSK 2849466

Alternative Names: GSK2849466

Latest Information Update: 12 Mar 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cachexia; Heart failure

Most Recent Events

  • 23 Jun 2014 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers presented at the Joint Meeting of the 16th International Congress of Endocrinology and the 96th Annual Meeting of the Endocrine Society (ICE/ENDO-2014)
  • 01 Feb 2014 Discontinued - Phase-I for Cachexia (In volunteers) in USA (PO) (GlaxoSmithKline pipeline, February 2014)
  • 01 Feb 2014 Discontinued - Phase-I for Heart failure in USA (PO) (GlaxoSmithKline pipeline, February 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top